Skip to content
Buy This GLP
← Research
Evidence

Tirzepatide against semaglutide: two doses nobody matched

Tirzepatide beat semaglutide by 2.87 kg in three months — at its lowest dose against semaglutide's second-highest. Appetite scores came out the same.

Carla Medina6 min read
What each drug was given at, against what it goes up tosemaglutide1.7 of 2.4 mgtirzepatide5 of 15 mgTirzepatide won by 2.87 kg. Appetite scores were the same.183 adults, one clinic, three months, nobody randomized.

This is the comparison the whole market is priced around, and the first thing to look at is not the result but the two doses somebody picked to produce it — because on this roster the dose is what the price is attached to.

What each drug was given at

Semaglutide at 1.7 mg a week. That is a real maintenance dose and it is one step below the 2.4 mg licensed for weight management. [1] Tirzepatide at 5 mg a week, which is the lowest of its three maintenance doses, with 10 and 15 mg above it.

So neither drug was at its ceiling, and they were not at matching points on their own ranges. A head-to-head is always a comparison of two chosen doses; this one chose a near-top dose of the drug that lost and the entry dose of the drug that won.

The result

Tirzepatide produced 2.87 kg more weight loss over three months, 95% CI 1.32 to 4.41, p < 0.001, along with greater reductions in total fat mass and visceral fat, and better insulin resistance measures.

The share reaching more than 10% body weight loss was 21.50 percentage points higher on tirzepatide, 95% CI 7.45 to 35.55, p = 0.003 — a gap between two proportions rather than a rate in its own right — a distinction worth holding onto, since a gap between proportions is the figure most often quoted as though it were one. Safety profiles were broadly similar.

What the design can carry

Three months, 183 people, one clinic, looked at retrospectively. Nobody was randomized, so whoever received which drug was placed there by a clinician for reasons the records do not capture.

It is also a single Chinese cohort, and neither body composition response nor prescribing practice is uniform across populations. The authors ask for larger and longer real-world studies before generalizing, which is the right request for a three-month before-and-after — the same limit as any comparison assembled from records rather than built by randomization.

What a buyer does with it

Note which doses won, and then check which doses you are being quoted. A result obtained at tirzepatide 5 mg says nothing about what tirzepatide 15 mg costs you per month, and on this roster those are frequently different prices.

The direction here agrees with the larger trial evidence, so nothing is overturned. What it adds is a reminder that a head-to-head is a head-to-head at two specific doses, and whether a seller holds its figure as the dose climbs decides what that comparison actually costs to act on.

Frequently asked

Which drug lost more weight?
Tirzepatide, by 2.87 kg over three months, 95% CI 1.32 to 4.41. It was given at 5 mg against semaglutide at 1.7 mg.
Were the doses equivalent?
No. Semaglutide's 1.7 mg is one step below the 2.4 mg licensed for weight; tirzepatide's 5 mg is the lowest of its three maintenance doses.
Did tirzepatide suppress appetite more?
Not in this study. Both drugs scored comparably on two validated questionnaires covering food cravings and appetite regulation, despite the difference in weight.
How strong is the evidence?
183 patients at one clinic over three months, looked at retrospectively with nobody randomized. The direction agrees with larger trials; the size should not be read across.

Sources

  1. [1] Yao Z, et al. (2026). Comparative Efficacy of Semaglutide and Tirzepatide in Chinese Adults with Obesity without Diabetes: A Real-World Observational Study Diabetes, Metabolic Syndrome and Obesity. PMID 42610030

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk

More in Evidence